Payload Information
General Information of This Payload
| Payload ID | PAY0KHZRQ |
|||||
|---|---|---|---|---|---|---|
| Name | Maytansine |
|||||
| Target(s) | Microtubule (MT) | |||||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
AGX101 [Phase 1]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 92.60% (Day 28) | High TM4SF1 expression (TM4SF1+++) | ||
| Method Description |
Mice bearingeither MIA PaCa-2 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
|
||||
| In Vivo Model | Pancreatic cancer CDX model | ||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | MIA PaCa-2 cells | CVCL_0428 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 93.40% (Day 23) | High TM4SF1 expression (TM4SF1+++) | ||
| Method Description |
Mice bearingeither MIA PaCa-2 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
|
||||
| In Vivo Model | Pancreatic cancer CDX model | ||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | MIA PaCa-2 cells | CVCL_0428 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 94.50% (Day 23) | High TM4SF1 expression (TM4SF1+++) | ||
| Method Description |
Mice bearingeither HCC1954 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
|
||||
| In Vivo Model | Breast ductal cancer CDX model | ||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 95.60% (Day 33) | High TM4SF1 expression (TM4SF1+++) | ||
| Method Description |
Mice bearingeither HCC1954 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
|
||||
| In Vivo Model | Breast ductal cancer CDX model | ||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.10% (Day 23) | High TM4SF1 expression (TM4SF1+++) | ||
| Method Description |
Mice bearingeither CALU-3 tumors were treated with either vehiclecontrol or AGX101 at 12 mg/kg g7dx2.
|
||||
| In Vivo Model | Lung adenocarcinoma CDX model | ||||
| In Vitro Model | Lung adenocarcinoma | Calu-3 cells | CVCL_0609 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.02 nM
|
High TM4SF1 expression (TM4SF1+++) | ||
| Method Description |
The inhibitory activity of AGX101 exerted a potent cytotoxic effect against TM4SF1+ cell lines.
|
||||
| In Vitro Model | Lung adenocarcinoma | A-549 cells | CVCL_0023 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.02 nM
|
High TM4SF1 expression (TM4SF1+++) | ||
| Method Description |
The inhibitory activity of AGX101 exerted a potent cytotoxic effect against TM4SF1+ solid tumor cell lines.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | MIA PaCa-2 cells | CVCL_0428 | ||